Phillip J. Koo, MD, presented “Therapeutic Radiopharmaceuticals in Prostate Cancer: What the Urologist Needs to Know” during the 30th Annual Perspectives in Urology: Point-Counterpoint, on March 12, 2023, at Humphreys Half Moon Inn, San Diego, California.
How to cite: Koo, Phillip J.,“Therapeutic Radiopharmaceuticals in Prostate Cancer: What the Urologist Needs to Know.” March 12, 2023. Accessed Aug 2024. https://grandroundsinurology.com/therapeutic-radiopharmaceuticals-in-prostate-cancer-what-the-urologist-needs-to-know/
Therapeutic Radiopharmaceuticals in Prostate Cancer: What the Urologist Needs to Know – Summary
Phillip J. Koo, MD, discusses radiopharmaceutical therapy to target and destroy cancer cells. He explains the different types of radiopharmaceuticals, including beta-emitting and alpha-emitting agents, and their respective advantages and limitations, highlighting radiopharmaceuticals currently used in clinical practice, such as Radium-223 and Lutetium-177.
He focuses on the clinical evidence supporting the use of radiopharmaceuticals in prostate cancer, noting that radiopharmaceuticals are particularly beneficial for patients with metastatic castration-resistant prostate cancer (mCRPC) who have limited treatment options.
Furthermore, Dr. Koo examines the future directions of radiopharmaceutical research, highlighting ongoing studies and emerging agents that hold promise for advancing prostate cancer treatment.
About the 30th Annual Perspectives in Urology: Point Counterpoint conference: Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, this conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking.
ABOUT THE AUTHOR
Phillip J. Koo, MD, is the Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine in Aurora, Colorado. He completed his fellowship at the Harvard Medical School Joint Program in Nuclear Medicine in Boston, Massachusetts. Dr. Koo is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine(ABNM).
